Physician profile
Jonette E Keri
NPI 1053396150
$36,492.96
in general payments reported to CMS, 2019-2025
14 companies · $4,250 in 2025
The $4,250 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,742 · 2020: $7,409 · 2021: $11K · 2022: $913 · 2023: $1,579 · 2024: $1,780 · 2025: $4,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,242 · Food and Beverage: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,241.50 |
| Food and Beverage | $367.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $10,279.58 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $7,230.00 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $5,978.39 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $4,239.63 | 2019-2022 | |
| Genzyme Corporation | $3,991.50 | 2025 | |
| Dermira, INC. | $2,685.80 | 2019 | |
| Almirall LLC | $1,450.64 | 2019-2022 | |
| Pfizer INC. | $308.22 | 2019-2023 | |
| Organon LLC | $139.16 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $119.14 | 2025 | |
| Organogenesis INC. | $26.21 | 2019 | |
| Acera Surgical, INC. | $16.12 | 2019 | |
| Abbvie INC. | $15.71 | 2020 | |
| Smith+Nephew, INC. | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonette Keri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.